{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:44:11Z","timestamp":1787244251891,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/mcg.0b013e31802f19af","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T07:57:10Z","timestamp":1236239830000},"page":"244-251","source":"Crossref","is-referenced-by-count":52,"title":["Patient Subjective Assessment of Drug Side Effects in Inflammatory Bowel Disease"],"prefix":"10.1097","volume":"42","author":[{"given":"Raymond K.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Lapshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210305","first-page":"477","article-title":"What do patients want to know about their inflammatory bowel disease?","volume":"24","author":"Martin","year":"1992","journal-title":"Ital J Gastroenterol"},{"key":"R2-5-20210305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"},{"key":"R3-5-20210305","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","author":"Kane","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R4-5-20210305","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2005.02429.x","article-title":"Polypharmacy and Crohn's disease","volume":"21","author":"Cross","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl","key":"R5-5-20210305","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjgastroenterol.2003.11.001","article-title":"Treatment of inflammatory bowel disease: safety and tolerability issues","volume":"98","author":"Navarro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R6-5-20210305","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.1997.03540280039031","article-title":"Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality","volume":"277","author":"Classen","year":"1997","journal-title":"JAMA"},{"key":"R7-5-20210305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","article-title":"Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group","volume":"274","author":"Bates","year":"1995","journal-title":"JAMA"},{"key":"R8-5-20210305","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"key":"R9-5-20210305","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2036.2001.00922.x","article-title":"Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk?","volume":"15","author":"Dormann","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-5-20210305","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1572-0241.2005.41598.x","article-title":"Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience","volume":"100","author":"Bajaj","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R11-5-20210305","first-page":"A362","article-title":"Proceedings of the American Thoracic Society 2005 International Conference","author":"Finkelstein","year":"2005"},{"key":"R12-5-20210305","first-page":"20","article-title":"The Side Effect Survey: a New Scale for Adverse Event Assessment","volume":"2","author":"Lapshin","year":"2005","journal-title":"R-AMA J"},{"key":"R13-5-20210305","first-page":"74","article-title":"How do pyschiatric patients perceive the side effects of their medications?","volume":"9","author":"Lapshin","year":"2006","journal-title":"German J Psychiatry"},{"key":"R15-5-20210305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"R16-5-20210305","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"R17-5-20210305","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"R18-5-20210305","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R19-5-20210305","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/j.1572-0241.2001.04682.x","article-title":"The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis","volume":"96","author":"Jowett","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R20-5-20210305","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"R21-5-20210305","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00002018-200225080-00003","article-title":"Comparative tolerability of therapies for ulcerative colitis","volume":"25","author":"Ardizzone","year":"2002","journal-title":"Drug Safety"},{"key":"R22-5-20210305","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2002.05596.x","article-title":"Corticosteroids in Crohn's disease","volume":"97","author":"Yang","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R23-5-20210305","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00002018-200023050-00006","article-title":"Comparative tolerability of treatments for inflammatory bowel disease","volume":"23","author":"Stein","year":"2000","journal-title":"Drug Safety"},{"key":"R24-5-20210305","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00002018-199106030-00005","article-title":"Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease","volume":"6","author":"Hanauer","year":"1991","journal-title":"Drug Safety"},{"key":"R25-5-20210305","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/00365520510023198","article-title":"Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease","volume":"40","author":"Erichsen","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"R26-5-20210305","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/j.1572-0241.2005.00256.x","article-title":"Narcotic use in patients with Crohn's disease","volume":"100","author":"Cross","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R27-5-20210305","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"R28-5-20210305","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1572-0241.2005.40849.x","article-title":"Are patients with inflammatory bowel disease receiving optimal care?","volume":"100","author":"Reddy","year":"2005","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004836-200803000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:46:47Z","timestamp":1786038407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-200803000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e31802f19af","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}